Cargando…
Differential expression of topoisomerase I and RAD52 protein in yeast reveals new facets of the mechanism of action of bisdioxopiperazine compounds
A screening procedure which permits identification of compounds based on their activities against specific biological targets directly in a living organism, Saccharomyces cerevisiae, has been established as part of our new drug discovery programme. Use of this assay has provided the first direct evi...
Autores principales: | Hille, B van, Clerc, X, Creighton, A M, Hill, B T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374289/ https://www.ncbi.nlm.nih.gov/pubmed/10555749 http://dx.doi.org/10.1038/sj.bjc.6690767 |
Ejemplares similares
-
Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
por: Jensen, Lars H, et al.
Publicado: (2004) -
Interaction of yeast Rad51 and Rad52 relieves Rad52-mediated inhibition of de novo telomere addition
por: Epum, Esther A., et al.
Publicado: (2020) -
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
por: Bavlovič Piskáčková, Hana, et al.
Publicado: (2021) -
A comprehensive structural analysis of the ATPase domain of human DNA topoisomerase II beta bound to AMPPNP, ADP, and the bisdioxopiperazine, ICRF193
por: Ling, Elise M., et al.
Publicado: (2022) -
Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations
por: Gonzalez, R, et al.
Publicado: (1999)